Nykode Therapeutics ASA (NYKD) — Cash Flow Reinvestment Rate

Latest as of March 2022: 0.15x

Nykode Therapeutics ASA (NYKD) has a Cash Flow Reinvestment Rate of 0.15x as of March 2022, reinvesting Nkr14.87 Million (capex Nkr14.06 Million plus investments Nkr817.00K) from operating cash flow of Nkr96.14 Million. Check NYKD cash flow quality index to evaluate the quality of earnings relative to operating cash generation.

Reinvestment Rate

0.15x

(Capex + Investments) / Operating CF

Total Reinvested

Nkr14.87 Million

Capex + Investments

Operating Cash Flow

Nkr96.14 Million

NOK

Capital Expenditures

Nkr14.06 Million

NOK

Nykode Therapeutics ASA Cash Flow Reinvestment Rate (2020–2021)

Historical reinvestment intensity for Nykode Therapeutics ASA across 2 annual periods. Explore Nykode Therapeutics ASA (NYKD) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.

Annual Cash Flow Reinvestment Rate for Nykode Therapeutics ASA (2020–2021)

Year-by-year capital reinvestment analysis for Nykode Therapeutics ASA. For live market cap and broader valuation context, see Nykode Therapeutics ASA stock valuation.

Year	Reinvestment Rate	Total Reinvested (NOK)	Operating CF	Capex	YoY Change
2021	10.58x	Nkr12.22 Million	Nkr1.16 Million	Nkr871.00K	▲ +31563.0%
2020	0.03x	Nkr6.03 Million	Nkr180.27 Million	Nkr99.00K	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow